Express Healthcare
Home  »  News  »  SynPhNe appoints Sabi Bivas as President, SynPhNe Health Inc, VP of IT and Data Infrastructure 

SynPhNe appoints Sabi Bivas as President, SynPhNe Health Inc, VP of IT and Data Infrastructure 

0 72
Read Article

Prior to the appointment, Bivas was with Merck for over 30 years where he established, headed Release Lifecycle Management, one amongst many other responsibilities over the years

SynPhNe announced the appointment of Sabi Bivas as President, SynPhNe Health Inc and VP of IT and Data Infrastructure. SynPhNe Health Inc, a wholly owned subsidiary of SynphNe headquartered in New Jersey, US.

Bivas is a senior healthcare executive with over 30 years of life sciences experience in establishing capabilities and leading strategic initiatives across various global business units and functions. Prior to the appointment, he was with Merck for over 30 years where he established and headed Release Lifecycle Management, one amongst many other responsibilities over the years.

Dr Subhasis Banerji, Founder and Managing Director, SynPhNe, said, “It gives us great pleasure to appoint Sabi Bivas at SynPhNe. Sabi comes with a wealth of experience: over three decades across a gamut of Healthcare IT operations like manufacturing, sales & marketing, research business units, compliance, product launches and automation. His dual role of subsidiary President and VP of IT and Data Infrastructure will play a vital role in further enhancing our growth and strengthen SynPhNe’s operating efficiencies and profitability.”

Dr Banerji added, “As we continue executing on our global strategy, we have reached another significant milestone by establishing our formal presence in the United States market. The key highlights of our plan there include setting up a clinic and deploying a digital marketing awareness campaign to establish a patient pipeline for delivering rehabilitation services to patients. Also, execute a large-scale adoption plan through partnership with an Accelerator, and by initiating the clinical trial with Boston-based leading rehabilitation hospital.”

Bivas on his new appointment said, “I look forward to building a significant presence of SynPhNe in this vast market keeping patient centricity at the core of what we do. In this age of COVID-19 and beyond, when reach and access to patients, in-person, will be restricted, SynPhNe technology is perfectly suited for patients to do therapy at home while being monitored remotely by their therapist”. 

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Want to know more about "Omic's" and it's relevance?
Register Now
close-image